June 22, 2023

ShareTreck: Jeff Galvin Weighs in on Addimmune’s Launch and AGT103-T Updates


View the full Article on:

Addimmune Summary

Addimmune™ CEO Jeff Galvin joins ShareTreck host Raj Natarajan in this compelling interview to discuss the company’s launch as well as updates on AGT103-T, Addimmune’s HIV therapeutic. Following a successful Phase 1 clinical trial, will build AGT’s success, accelerating the clinical development with dedicated investment and singular focus on HIV.